NCT01095484

Named Patient Program With Rotigotine Transdermal System

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 520 (actual)
• Sponsor: UCB Pharma · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The named patient program will allow investigators to supply rotigotine transdermal system to patients who have a documented medical necessity to receive treatment with the drug.

Conditions

• Conditions for Which There is a Documented Medical Necessity to Receive Treatment With Rotigotine

Interventions

Type	Name	Description
DRUG	Rotigotine patch	1 patch daily for up to 48 months. Patch strength (per 24 hours): 1 mg - 8 mg based on investigator's assessment

Timeline

• Start date: 2008-11-01
• Primary completion: 2012-12-01
• Completion: 2012-12-01
• First posted: 2010-03-30
• Last updated: 2014-10-20

Locations

51 sites across 1 country: United States